Snapshot from Jul 07, 2026 at 07:00 UTC. For live data and tracking: View Live
Entity

BeOne Medicines

Tracked across 4 events · 24 articles · First seen Apr 13, 2026 · Last active Jun 30, 2026

Sentiment
42
Attention
6
Events
4
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
2 50
Business
Impact: BeOne Medicines received the 'Outstanding Global Oncology Company of the Year' award, recognizing its advancements in R&D and manufacturing of cancer therapies, which positively impacts its reputation and market standing.
May 11, 2026 · 6 articles
6 90
Tech
Impact: BeOne Medicines announced positive topline results from its Phase 3 MANGROVE study for Zanubrutinib, which is expected to significantly boost its market position and future revenue in oncology.
Jun 30, 2026 · 6 articles
4 30
Tech
Impact: BeOne Medicines provided Tislelizumab under a clinical drug supply agreement for AnBogen Therapeutics's Phase 1/2 clinical trial.
Apr 13, 2026 · 6 articles
2 0
Business
Impact: Dr. Michelle Mellion previously held a Chief Medical Officer role at BeOne Medicines, leading clinical development efforts.
May 12, 2026 · 6 articles
100 BeOne Medicines announced positive resultsBeOne BRUKINSA Phase 3 Success
80 BeOne Medicines planned regulatory submissionsBeOne BRUKINSA Phase 3 Success
ERGEN INTELLIGENCE
Track BeOne Medicines live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.